Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, saw a substantial amount of new information related to the treatment and prevention of 

. Oral anticoagulants and AI demonstrated their protective capacity for several forms of stroke, while NOAC monotherapy reduced subclinical leaflet thrombosis after transcatheter aortic valve implantation. However, not all major trials presented over the 4 days of the conference succeeded: ENRICH-AF and LIBREXIA ACS both failed to meet their primary endpoints.

Of course, even a failed trial still serves an educational or informative purpose, and with so many trials presented in the stroke space during this conference, the 

 editorial team has collected 5 of the most impactful headlines to release at ESC 2026. Catch up on any stroke information you may have missed below:


ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans

The ORFAN-MAESTRIA trial, enrolling >80,000 patients and lasting for 10 years, displayed the efficacy of AI deep learning models in identifying and predicting cardioembolic stroke and 

 from routine computed tomography (CT) scans. Presented by Charalambos Antoniades, MD, PhD, director of the Acute Multidisciplinary Imaging & Interventional Centre and founder and chief scientific officer at Caristo Diagnostics, the trial opens up a new pathway to identifying atrial myopathy before it occurs and preventing the ensuing cardiovascular damage.


ACASA-TAVI: NOAC Monotherapy Cuts Leaflet Thrombosis

Anticoagulation monotherapy after transcatheter aortic valve implantation demonstrated a significant reduction in subclinical leaflet thrombosis while remaining noninferior for bleeding, thromboembolic events, and death compared with antiplatelet monotherapy. ACASA-TAVI, presented by Øyvind Lie, MD, PhD, MSc, of Oslo University Hospital Rikshospitalet and the principal investigator in the trial, represents a direct contradiction to the widely-accepted belief that oral anticoagulants carry a higher bleeding risk for these patients.


ENRICH-AF: A Dosing Clue Emerges After Edoxaban's Miss, With Ashkan Shoamanesh, MD

Why Edoxaban Failed in ENRICH-AF, With Ashkan Shoamanesh, MD

ENRICH-AF is the largest randomized trial conducted in patients with atrial fibrillation and intracranial hemorrhage. However, edoxaban treatment failed to significantly reduce the primary composite endpoint of stroke or systemic embolism compared with no anticoagulation and led to greater rates of ISTH major bleeding in treated patients. In an interview with 

, Ashkan Shoamanesh, MD, of McMaster University, principal investigator of the trial, discusses the tradeoff between the slightly reduced stroke risk and the substantially increased bleeding risk.


LIBREXIA ACS Fails to Improve Cardiovascular Outcomes, Doesn’t Increase Bleeding Risk

LIBREXIA-ACS Fails to Improve Cardiovascular Outcomes, Doesn’t Increase Bleeding Risk

The LIBREXIA ACS study, aiming to investigate milvexian in reducing cardiovascular events following acute coronary syndrome, ultimately failed to achieve superiority to placebo and was terminated early. Despite this, as Philippe Gabriel Steg, MD, professor of cardiology at the Université Paris, stated in an interview with 

, milvexian’s investigative pathway is far from over – the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials, reporting in 2027, will further delve into the drug’s potential cardioprotective effects.


SINGLE-AF: Oral Anticoagulants Reduce Risk of Stroke in Patients With AF

The evidence to support anticoagulants in patients with atrial fibrillation who are at intermediate risk of stroke has traditionally been conflicting. The SINGLE-AF trial, presented by Boyoung Joung, MD, from the Yonsei University College of Medicine in South Korea, took the first step towards redefining this treatment method in this population. With a total of 1803 patients enrolled, the trial demonstrated a substantial reduction in a composite endpoint of stroke, systemic embolism, major bleeding, and cardiovascular death over 24 months.

Articles

ESC 2026 in Munich delivered stroke-focused readouts spanning AI-enabled risk prediction, post-TAVI antithrombotic strategy, and nuanced anticoagulation decisions in high-bleeding-risk AF. A decade-long, >80,000-patient effort suggested deep-learning models can infer future cardioembolic stroke and atrial fibrillation from routine CT imaging, enabling earlier detection of atrial myopathy. After TAVI, NOAC monotherapy reduced subclinical leaflet thrombosis without excess bleeding versus antiplatelet therapy. Conversely, edoxaban after prior intracranial hemorrhage increased major bleeding without significantly lowering thromboembolism, and milvexian in ACS was neutral.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Arrhythmia

Videos

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

ESC 2026 Stroke Spotlight Recap: 5 Practice-Changing Trials to Know

Jim Blando, PhD, chair of the Department of Epidemiology, Biostatistics, and Environmental Health at Old Dominion University

Wynne Armand, MD, from Massachusetts General Hospital.

are documenting a wildfire health effect that extends well past the smoky week that makes headlines.

Most wildfire smoke research centers on its cardiopulmonary effects, with fine particulate matter linked to asthma flare-ups, heart attacks, and strokes. California studies tied children's smoke exposure to more coughing, wheezing, bronchitis, colds, and asthma-related doctor or hospital visits. Wildfires also release carbon monoxide, and inhaling it limits oxygen delivery to the body's organs and tissues, causing headaches, nausea, and dizziness, and at high levels, death.

Wildfire Smoke's Hidden Toll on Patients with Allergies

The Link Between Wildfire Smoke & Allergies

However, little research focuses on the link between wildfire smoke and allergies.

An observational study published in 2022 reported that patients at a local allergy clinic in northeastern North Carolina showed measurable declines in lung function a full year after exposure to wildfire smoke from 2 peat bog fires (2008 and 2011) in the Great Dismal Swamp. Investigators reviewed 5 years of clinical records for 842 patients with allergic rhinitis and/or asthma, using peak flow measurements and wind direction as a proxy for smoke exposure, and found that deficits were consistently worse one year after the fires than during them.

For every 1 percent increase in time the wind blew from the fire toward the community, peak flow dropped by an average of 2.21 liters per minute, with the steepest declines seen in women, Black patients, and under strong wind conditions. These findings held up even after adjusting for age, sex, race, and BMI, suggesting the smoke exposure itself, not just demographic factors, was driving the delayed drop in lung function. The authors proposed that wildfire smoke may act as an adjuvant, heightening patients' allergic sensitivity or triggering a delayed immune response that doesn't surface until months later.

"We didn't see anything initially during the actual wildfire or immediately thereafter," said investigator Jim Blando, PhD, chair of the Department of Epidemiology, Biostatistics, and Environmental Health at Old Dominion University, in an interview with 

Blando compares the pattern to how the body responds to poison ivy: the first exposure may not trigger a reaction, but repeated exposure builds sensitization. He also points to climate change more broadly, noting longer growing seasons and earlier pollen production are compounding the problem alongside wildfire smoke.

At Massachusetts General Hospital, Wynne Armand, MD, has watched a related pattern unfold in dermatology records.

Eczema flare visits spiked sharply during recent wildfire seasons, tracking closely with air pollution severity. Armand explains patients with eczema already have a weakened skin barrier, making it easier for smoke particles to trigger a stronger immune response.

Both experts caution the underlying science is still developing. Armand said understanding wildfire smoke's specific contribution to allergic disease, not just symptom flares, “will be a very critical piece” of future research.

In the meantime, both recommend a mix of monitoring air quality, minimizing outdoor exposure during smoke events, wearing a properly fitted N95 respirator, and for skin protection, using mineral-based sunscreen and rinsing exposed skin after being outdoors.

“I personally feel pretty confident that as we look into it further, we are going to find a lot of evidence supporting that wildfire smoke is very allergenic,” Blando said.

Blando J, Allen M, Galadima H, Tolson T, Akpinar-Elci M, Szklo-Coxe M. Observations of Delayed Changes in Respiratory Function among Allergy Clinic Patients Exposed to Wildfire Smoke. Int J Environ Res Public Health. 2022 Jan 22;19(3):1241. 

doi: 10.3390/ijerph19031241. PMID: 35162264; PMCID: PMC8835059.

Armand W. One surprising effect of wildfires: Itchy, irritated skin. Harvard Health Publishing. June 24, 2024. Accessed September 9, 2026. 

https://www.health.harvard.edu/blog/one-surprising-effect-of-wildfires-itchy-irritated-skin-202406243052

Research suggests wildfire smoke does more than irritate the airways in the moment; it may worsen allergic disease for months afterward.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

David Oberlin, MD, a board-certified dermatologist at Forefront Dermatology in Grand Rapids, Michigan, spoke with 

 about a commentary he co-authored with Jesse Veenstra, MD, PhD, of Henry Ford Health, in the 

Journal of the American Academy of Dermatology (JAAD)

 label update crediting guselkumab (Tremfya) with inhibiting radiographic joint damage in psoriatic arthritis (PsA), based on the phase 3b APEX trial (NCT04882098), and asks whether its enriched population reflects general dermatology patients.

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD

Oberlin said APEX enrolled biologic-naive patients with erosive disease, elevated CRP, and PsA duration beyond 6 months, criteria he called far more restrictive than those used in comparator trials such as DISCOVER-2 and KEEPsAKE 1. He and Veenstra found baseline joint damage closely tracked how much a trial's placebo arm progressed on radiographic Sharp scores, making a statistically significant treatment effect easier to reach in a more enriched population regardless of the drug's mechanism.

Oberlin said this relationship helps explain why APEX reached significance on its radiographic endpoint while DISCOVER-2, also testing guselkumab, and KEEPsAKE 1, testing risankizumab (Skyrizi), did not, despite guselkumab and risankizumab both working through interleukin (IL)-23 inhibition. He noted no head-to-head trial exists comparing the 2 drugs directly on joint damage outcomes.

"The biggest message we want to get across to providers is make sure the baseline characteristics of the trial represent the patient in front of you. If the patient in front of you fits the APEX trial, then you may be able to inhibit radiographic progression, but otherwise you cannot look at that study and say it has mechanistic superiority compared to other IL-23 agents," Oberlin said.

Oberlin said APEX alone would not change how he selects a biologic for psoriatic disease. He weighs oral versus injectable preference, disease severity, comorbidities, how quickly a patient needs to clear, dosing frequency, and formulary coverage, and said dermatologists now have enough effective IL-23 and IL-17 options, so no single trial should dictate the choice.

Editor’s note: Oberlin disclosed having received honoraria for serving as a key opinion leader for Amgen, AbbVie, UCB, and Arcutis, and for participating on advisory boards for AbbVie, Sensus, UCB, Sanofi, Incyte, and Apogee. This transcript has been edited for grammar and clarity using artificial intelligence tools.

Oberlin D, Veenstra J. Interpreting radiographic outcomes across IL-23 inhibitor trials in psoriatic arthritis: the role of trial design. J Am Acad Dermatol. Published online 2026. doi:10.1016/j.jaad.2026.06.135.

Smith T. Trial Design Drives Radiographic Outcomes Across IL-23 Inhibitors in PsA. HCPLive. August 26, 2026. Accessed September 9, 2026. 

https://www.hcplive.com/view/trial-drives-radiographic-outcomes-il-23-inhibitors-psa

FDA approves label expansion cementing Tremfya as the only IL-23 inhibitor proven to help stop further joint damage. Johnson & Johnson. Published May 28, 2026. Accessed September 9, 2026.

David Oberlin, MD, on why trial enrichment, not mechanistic superiority, likely explains differing radiographic results in PsA drug trials.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Njira Lugogo, MD, from University of Michigan.

New subgroup data from the phase 2b AIRCULES trial show that lunsekimig, Sanofi's bispecific Nanobody targeting both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), produced larger exacerbation reductions in patients with more severe or biomarker-high 

, according to Njira Lugogo, MD, MS, clinical professor of medicine and director of the Michigan Medicine Asthma Program at the University of Michigan. Lugogo discussed the data, presented at the 

European Respiratory Society (ERS) Congress 2026

 in Barcelona, Spain, held September 5 to 9, in an interview with 

AIRCULES Subgroup Data Show Lunsekimig Benefit Scales With Severity

“I'm really excited about lunsekimig specifically because this is the first bispecific biologic that we have in asthma,” she said, noting that most existing biologics target a single pathway despite evidence of redundant, overlapping inflammatory mechanisms in severe disease.

AIRCULES previously met its primary and key secondary endpoints compared with placebo, with lunsekimig added to standard of care in adults with moderate-to-severe asthma across the full range of fractional exhaled nitric oxide (FeNO) and eosinophil values.

 Lugogo said the annualized exacerbation reduction was about 39% in the overall population, rising to 55% at the highest dose tested (300 mg every 4 weeks). The effect was more pronounced in prespecified subgroups: patients with a history of more than 3 exacerbations had nearly an 80% reduction, those with high baseline FeNO had a significant exacerbation reduction alongside a lung function improvement and met the minimal clinically important difference on the Asthma Control Questionnaire, and patients with eosinophil counts above 300 cells/µL also showed a more robust response than the overall population, including improved forced expiratory volume in 1 second.

Lugogo said the dual-target mechanism has a specific rationale beyond simply combining 2 pathways: blocking TSLP upstream may help offset the eosinophil increase sometimes seen with IL-13 blockade alone, while both pathways have independently been linked to mucus reduction and lung function improvement. She also pointed to lunsekimig's potential to address comorbid type 2 conditions, such as sinonasal disease and atopic dermatitis, beyond asthma itself, based in part on her own clinical experience using dual-biologic combinations in patients with overlapping disease. On safety, she said the novel Nanobody platform showed a low rate of anti-drug antibodies and treatment-emergent adverse events similar between placebo and treatment arms, with no signals prompting concern heading into phase 3.

Lugogo said the subgroup data are meant to inform which patients should be prioritized in the phase 3 program and to help settle on a single dose going forward. She framed the results within a broader unmet need: only about 35% of patients with severe asthma currently achieve remission, and she said dual-pathway blockade could help expand that proportion. An early-intervention study of lunsekimig in high-risk patients, AIRLYMPUS, is expected to read out results next year.

Sanofi. Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP. Published April 7, 2026.

ClinicalTrials.gov. A study of lunsekimig (SAR443765) in adult participants with moderate to severe asthma (AIRCULES). Identifier: NCT06102005.

Lunsekimig, a bispecific Nanobody targeting TSLP and IL-13, showed enhanced exacerbation reduction in moderate-to-severe asthma, with larger effects in severe and biomarker-high subgroups. Overall annualized exacerbations fell ~39%, increasing to ~55% at 300 mg every 4 weeks. Patients with >3 prior exacerbations approached ~80% reduction, while high FeNO and eosinophils >300 cells/µL correlated with greater clinical benefit, including improved FEV1 and ACQ minimal clinically important difference attainment. Safety appeared comparable to placebo with low immunogenicity.

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD

One interesting take-home point is how nonspecific some of the presenting symptoms can be. People with rare diseases tend to have a lot of false starts before something is actually found, because common things being common, it's not the first thing that most people think about.

Closing the Diagnostic Delay Gap in IgA Nephropathy, With Gaia Coppock, MD

Gaia Coppock, MD, is an associate professor of clinical medicine in the Division of Renal-Electrolyte and Hypertension and an attending physician at the Hospital of the University of Pennsylvania in Philadelphia. She directs the hospital's Glomerular Disease Clinical Research Program and its Kidney Biopsy Group, and directs the Lupus Nephritis Program at the University of Pennsylvania School of Medicine. She discussed the findings and what they mean for nephrology practice in an interview with HCPLive.

A poster presented at GlomCon 2026, the annual meeting for glomerular disease specialists held in Maui, Hawaii, put new numbers behind a familiar concern in IgA nephropathy (IgAN): symptom-driven delays between first presentation and diagnosis. The Vertex Pharmaceuticals-sponsored study paired 20 qualitative interviews with a 106-patient survey of the IgAN journey. It builds on 

recent HCPLive coverage of diagnostic gaps in IgAN

Patients most often presented with hematuria or fatigue, symptoms Coppock said are easy to miss or misattribute; hematuria, for example, is frequently mistaken for a urinary tract infection. Abnormal labs, including elevated urine protein (82%) and hematuria (70%), were usually what triggered a nephrology referral, and wait times stretching toward a year can put a patient's diagnosis roughly two years behind symptom onset.

Coppock noted once patients reach a nephrologist, the workup typically moves quickly, but many still described feeling confused after diagnosis and turned to the internet or patient advocacy groups to fill gaps, even though about 85% named their doctor as their primary source of information, and 57% said they would rather get it from their nephrologist specifically.

The survey also found a gap between what patients want from treatment and what they feel they're getting: 80% wanted symptoms stopped, but only 49% felt therapy delivered, with similar shortfalls for slowing kidney function loss (78% vs 50%) and delaying dialysis (75% vs 50%). Closing this gap carries real stakes: time-averaged proteinuria above 0.5 g/day has been linked to a higher risk of kidney failure in adults with IgAN.²

Her message to primary care: even low suspicion for IgAN warrants a urine check and follow-up, because earlier recognition offers more treatment options and, in her view, more hope for preserving kidney function.

Editor’s Note: Coppock reports relevant disclosures with 

Bensouda M, Wade B, Burns J, et al. IgA Nephropathy Patient Experience: A Qualitative and Quantitative Mixed-Methodology Study. Poster presented at: GlomCon 2026; August 3-7, 2026; Maui, HI.

Shah A, Gagnon-Sanschagrin P, Bedard J, et al. Time-averaged proteinuria ≤0.5 g/day is associated with kidney failure in adult patients with IgA nephropathy in the US. Poster presented at: National Kidney Foundation Spring Clinical Meetings; 2026; New Orleans, LA.

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know

Ankeet Bhatt, MD, is a research scientist at Kaiser Permanente Northern California and an associate physician at Kaiser San Francisco Medical Center.

Ankeet Bhatt, MD, MBA, discusses the effectiveness of text, email, and secure portal message reminders for encouraging patients to keep up with their treatment.

Atherosclerotic Cardiovascular Disease

ADHERE-ASCVD: Digital Reminders Improve Refill Rates, Adherence to Statins in ASCVD

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD

Owen Muir, MD, DFAACAP, FCTMSS, co-founder and chief medical officer at Radial.

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD

Leon Kircik, MD, on why an FDA-approved, at-home molluscum option changes practice, and what is exciting for him in dermatology.

Why Molluscum No Longer Means 'Watch and Wait,' With Leon Kircik, MD

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Dyslipidemia

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ESC 2026 Recap: 5 Practice-Changing Trials to Know

 Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD

Sharmila Dorbala, MD, MPH, is the director of nuclear cardiology at Brigham and Women’s Hospital and the director of amyloidosis research at Mass General Brigham Heart & Vascular Institute.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

REVEAL: I-124 Evuzamitide PET/CT Specific, Sensitive for Cardiac Amyloidosis Diagnosis

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Latest News

ESC 2026 Stroke Spotlight Recap: 5 Practice-Changing Trials to Know

Wildfire Smoke's Hidden Toll on Patients with Allergies

What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD